Intra-intestinal inactivation of residual antibiotics as a promising approach to fight against antimicrobial resistance.

Antimicrobial resistance (AMR) is a grave threat to public health causing 50000 deaths per year in the US and Europe alone. With virtually no new antibiotic classes created in the new millennia, identifying novel strategies to preserve and extend the useful life of existing antibiotics has therefore become a priority. Human intestinal bacteria is considered as reservoirs for AMR antibiotic resistance genes. In fat, the incomplete absorption of oral antibiotics and the secretion of intestinal disturb the colonization resistance of the intestinal microbiota that leads to the selection, emergence and transfer of AMR. The PhD project is a multidisciplinary study aiming to design and develop intra-intestinal inactivating systems capable of eradicating the residual antibiotics and maintain the intestinal microbiota stability and therefore block this AMR generator. New inactivating agents will be identified and their inactivation capacity towards a wide range antibiotics will be assessed and validated. The inactivating agents will be formulated in pharmaceutical delivery systems to target different segments of the gastrointestinal track and maintain its microbiota stability.